Laureate Pharma and Selexis SA, a Swiss-based contract developer of high performance production cell lines, will continue their collaboration via a joint marketing agreement.

The collaboration will access complementary contract services in an effort to generate highly productive, stable mammalian cells producing gram quantities of recombinant protein materials in as few as eight weeks, post transfection. Additionally, the companies will simultaneously work to develop cGMP manufacturing processes for a streamlined approach for the production of clinical-grade material.

"We are pleased to be working with Selexis and their highly advanced approach to developing high performance production cell lines," said Dr. Robert Broeze, president and chief executive officer of Laureate Pharma. "Combining the Selexis approach to cell line development with our strong track-record of cGMP manufacturing provides a very compelling value proposition for clients looking to outsource biopharmaceutical manufacturing."

"Including Laureate in our network of manufacturing partners is of great benefit to our clients seeking a US based manufacturer with a long history of successful cGMP compliant manufacturing," said Dr. Igor Fisch, president and chief executive officer of Selexis. "Laureate is a leader in this area and we are very pleased to be in association with this strong organization."